HRP20210389T1 - Višespecifične konstrukcije antitijela - Google Patents
Višespecifične konstrukcije antitijela Download PDFInfo
- Publication number
- HRP20210389T1 HRP20210389T1 HRP20210389TT HRP20210389T HRP20210389T1 HR P20210389 T1 HRP20210389 T1 HR P20210389T1 HR P20210389T T HRP20210389T T HR P20210389TT HR P20210389 T HRP20210389 T HR P20210389T HR P20210389 T1 HRP20210389 T1 HR P20210389T1
- Authority
- HR
- Croatia
- Prior art keywords
- multispecific antibody
- antibody molecule
- molecule according
- seq
- sek
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000012404 Orosomucoid Human genes 0.000 claims 1
- 108010061952 Orosomucoid Proteins 0.000 claims 1
- 102000007584 Prealbumin Human genes 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- 102000009488 Thyroxine-Binding Proteins Human genes 0.000 claims 1
- 108010048889 Thyroxine-Binding Proteins Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Molekula višespecifičnog antitijela naznačena time da se sastoji od:
a) polipeptidnog lanca formule (I):
VH-CH1-X-V1;
i
b) polipeptidnog lanca formule (II):
VL-CL-Y-V2;
gdje:
VH predstavlja varijabilnu domenu teškog lanca;
CH1 predstavlja domenu konstantnog područja teškog lanca, na primjer, njegovu domenu 1;
X predstavlja vezu ili linker;
Y predstavlja vezu ili linker;
V1 predstavlja dsscFv;
VL predstavlja varijabilnu domenu lakog lanca;
CL predstavlja domenu iz konstantnog područja lakog lanca, kao što je Ckappa;
V2 predstavlja dsscFv
pri čemu svaki od VH/VL, V1 i V2 formira mjesto vezivanja antigena, i
pri čemu samo jedan od VH/VL, V1 ili V2 ima specifičnost za serumski protein nosač.
2. Molekula višespecifičnog antitijela prema patentnom zahtjevu 1, naznačena time da je serumski protein nosač izabran sa liste koju čine albumin, tiroksin-vezujući protein, transtiretin, α1-kiseli glikoprotein, transferin i fibrinogen, ili fragment bilo kojeg od njih.
3. Molekula višespecifičnog antitijela prema patentnom zahtjevu 1 ili 2, naznačena time da je serumski protein nosač humani serum albumin i što spomenuti VH/VL ili V1 ili V2 koji imaju specifičnost za serumski protein nosač formiraju mjesto vezivanja za albumin.
4. Molekula višespecifičnog antitijela prema patentnom zahtjevu 3, naznačena time da mjesto vezivanja za albumin sadrži SEK ID BR: 71 za CDRH1, SEK ID BR: 72 za CDRH2, SEK ID BR: 73 za CDRH3, SEK ID BR: 74 za CDRL1, SEK ID BR: 75 za CDRL2 i SEK ID BR: 76 za CDRL3; ili varijabilni domenu teškog lanca izabranu između SEK ID BR: 77 i SEK ID BR: 78 i varijabilni domenu lakog lanca izabranu između SEK ID BR: 79 i SEK ID BR: 80.
5. Molekula višespecifičnog antitijela prema patentnom zahtjevu 4, naznačena time da su 6 CDR-a u SEK ID BR: 71 do SEK ID BR: 76, ili varijabilni domeni u SEK ID BR: 77 do SEK ID BR: 80 u položaju VH/VL ili V1 ili V2.
6. Molekula višespecifičnog antitijela prema patentnom zahtjevu 4 ili 5, naznačena time da se varijabilna domena teškog lanca sekvence SEK ID BR: 78 i varijabilna domena lakog lanca sekvence SEK ID BR: 80 nalaze u položaju V2 i pri čemu je varijabilna domena lakog lanca ili varijabilni domena teškog lanca V2 vezan za Y, na primjer kroz peptidnu vezu.
7. Molekula višespecifičnog antitijela prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačena time da je molekula antitijela sposoban da selektivno vezuje dva ili više različitih antigena od značaja.
8. Molekula višespecifičnog antitijela prema bilo kojem od patentnih zahtjeva od 1 do 7, naznačena time da su varijabilni domeni lakog i teškog lanca V1 i/ili varijabilni domeni lakog i teškog lanca V2 povezani disulfidnom vezom između dva inženjirana cisteinska ostatka, pri čemu je položaj para cisteinskih ostataka VH44 i VL100 (numeracija prema Kabatu).
9. Molekula višespecifičnog antitijela prema bilo kojem od patentnih zahtjeva od 1 do 8, naznačena time da X i/ili Y predstavljaju peptidni linker, na primjer SEK ID BR: 1, 2, 69 i 70.
10. Polinukleotid, naznačen time da kodira molekulu višespecifičnog antitijela prema bilo kojem od patentnih zahtjeva od 1 do 9.
11. Vektor, naznačen time da sadrži polinukleotid definiran u patentnom zahtjevu 10.
12. Stanica domaćina, naznačena time da sadrži polinukleotid ili vektor iz patentnog zahtjeva 10 ili 11, odnosno.
13. Stanica domaćina, naznačena time da sadrži dva vektora, prvi vektor koji sadrži polinukleotid koji kodira polipeptidni lanac formule (I) molekula višespecifičnog antitijela prema bilo kojem od patentnih zahtjeva od 1 do 9, i drugi vektor koji sadrži polinukleotid koji kodira polipeptidni lanac formule (II) spomenute molekule višespecifičnog antitijela.
14. Postupak, naznačen time da obuhvaća ekspresiju molekula višespecifičnog antitijela iz stanice domaćina definiranog u patentnom zahtjevu 12 ili patentnom zahtjevu 13.
15. Farmaceutski pripravak, naznačen time da sadrži molekulu višespecifičnog antitijela prema bilo kojem od patentnih zahtjeva od 1 do 9 i najmanje jedan ekscipijent.
16. Molekula višespecifičnog antitijela prema bilo kojem od patentnih zahtjeva od 1 do 9 ili farmaceutska kompozicija prema patentnom zahtjevu 15, naznačena time da je za upotrebu u liječenju.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411320.3A GB201411320D0 (en) | 2014-06-25 | 2014-06-25 | Antibody construct |
| EP19169534.5A EP3556777B1 (en) | 2014-06-25 | 2015-06-25 | Multispecific antibody constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210389T1 true HRP20210389T1 (hr) | 2021-04-16 |
Family
ID=51410123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191775TT HRP20191775T1 (hr) | 2014-06-25 | 2019-10-01 | Multispecifične konstrukcije antitijela |
| HRP20210389TT HRP20210389T1 (hr) | 2014-06-25 | 2021-03-08 | Višespecifične konstrukcije antitijela |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191775TT HRP20191775T1 (hr) | 2014-06-25 | 2019-10-01 | Multispecifične konstrukcije antitijela |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11345760B2 (hr) |
| EP (2) | EP3556777B1 (hr) |
| JP (1) | JP6765974B2 (hr) |
| KR (1) | KR102271204B1 (hr) |
| CN (1) | CN106459216B (hr) |
| AU (2) | AU2015279128B2 (hr) |
| BR (1) | BR112016027585A2 (hr) |
| CA (1) | CA2951609C (hr) |
| CL (1) | CL2016003324A1 (hr) |
| CY (2) | CY1122175T1 (hr) |
| DK (2) | DK3161007T3 (hr) |
| ES (2) | ES2866398T3 (hr) |
| GB (1) | GB201411320D0 (hr) |
| HR (2) | HRP20191775T1 (hr) |
| HU (2) | HUE046027T2 (hr) |
| IL (1) | IL249003B (hr) |
| LT (2) | LT3161007T (hr) |
| ME (1) | ME03539B (hr) |
| MX (1) | MX2016015952A (hr) |
| MY (2) | MY176332A (hr) |
| PL (2) | PL3161007T3 (hr) |
| PT (2) | PT3161007T (hr) |
| RS (2) | RS59416B1 (hr) |
| RU (1) | RU2725812C2 (hr) |
| SG (2) | SG10201911670QA (hr) |
| SI (2) | SI3161007T1 (hr) |
| WO (1) | WO2015197772A1 (hr) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201400193SA (en) * | 2011-09-16 | 2014-05-29 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| CN109071643B (zh) | 2016-05-01 | 2024-03-19 | Ucb生物制药有限责任公司 | 亲和力改造的血清蛋白载体结合结构域 |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201811368D0 (en) | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
| MA53903A (fr) | 2018-10-16 | 2021-08-25 | UCB Biopharma SRL | Méthode de traitement de la myasthénie grave |
| GB201900732D0 (en) | 2019-01-18 | 2019-03-06 | Ucb Biopharma Sprl | Antibodies |
| GB201906835D0 (en) | 2019-05-15 | 2019-06-26 | Ucb Biopharma Sprl | Dry microparticles |
| SG11202112000YA (en) | 2019-06-20 | 2021-11-29 | UCB Biopharma SRL | Hplc-based detection of flocculation agents in a protein sample |
| AU2020326087A1 (en) | 2019-08-02 | 2021-12-16 | UCB Biopharma SRL | Methods for purifying antibodies |
| CN113416258B (zh) * | 2019-10-24 | 2023-08-29 | 北京免疫方舟医药科技有限公司 | 一种多特异性抗体及其制备方法和用途 |
| GB201917480D0 (en) | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
| GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| TW202202520A (zh) | 2020-03-27 | 2022-01-16 | 比利時商Ｕｃｂ生物製藥公司 | 自主旋鈕(autonomous knob)結構域肽 |
| US20230176071A1 (en) | 2020-05-08 | 2023-06-08 | UCB Biopharma SRL | Arrays and methods for identifying binding sites on a protein |
| GB202012991D0 (en) | 2020-08-20 | 2020-10-07 | Ucb Biopharma Sprl | Cell culture processes |
| US20230374158A1 (en) | 2020-10-13 | 2023-11-23 | Almirall, S.A. | Bispecific molecules and methods of treatment using the same |
| KR20230087552A (ko) | 2020-10-15 | 2023-06-16 | 유씨비 바이오파마 에스알엘 | Cd45를 다량체화하는 결합 분자 |
| CA3197465A1 (en) | 2020-11-02 | 2022-05-05 | UCB Biopharma SRL | Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders |
| GB202018889D0 (en) | 2020-12-01 | 2021-01-13 | UCB Biopharma SRL | Formulations |
| JP2023551983A (ja) | 2020-12-07 | 2023-12-13 | ユーシービー バイオファルマ エスアールエル | インターロイキン－２２に対する抗体 |
| IL303295A (en) | 2020-12-07 | 2023-07-01 | UCB Biopharma SRL | Multispecific antibodies and antibody combinations |
| US20240036054A1 (en) | 2021-02-04 | 2024-02-01 | Rq Biotechnology Limited | Antibodies |
| WO2022174813A1 (zh) * | 2021-02-19 | 2022-08-25 | 信达生物制药(苏州)有限公司 | 抗GPRC5DxBCMAxCD3三特异性抗体及其用途 |
| GB202103785D0 (en) | 2021-03-18 | 2021-05-05 | UCB Biopharma SRL | Formulations |
| EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
| GB202105424D0 (en) | 2021-04-16 | 2021-06-02 | UCB Biopharma SRL | Cell culture processes |
| JP2024516305A (ja) | 2021-05-03 | 2024-04-12 | ユーシービー バイオファルマ エスアールエル | 抗体 |
| WO2022238321A1 (en) | 2021-05-10 | 2022-11-17 | UCB Biopharma SRL | Process for the production of recombinant proteins |
| GB202107153D0 (en) | 2021-05-19 | 2021-06-30 | UCB Biopharma SRL | Method for filling vials containing liquid drug products |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| GB202115127D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115122D0 (en) | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
| GB202115121D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202116665D0 (en) | 2021-11-18 | 2022-01-05 | UCB Biopharma SRL | Method for the treatment of a scleroderma disease |
| TW202334240A (zh) | 2021-11-18 | 2023-09-01 | 比利時商Ｕｃｂ生物製藥公司 | 治療進行性慢性間質性肺部疾病之方法 |
| GB202118010D0 (en) | 2021-12-13 | 2022-01-26 | UCB Biopharma SRL | Method for detecting and/or quantifying crosslinks formed by transglutaminases |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| WO2023242238A1 (en) | 2022-06-15 | 2023-12-21 | UCB Biopharma SRL | Cell culture processes |
| WO2024079114A1 (en) | 2022-10-11 | 2024-04-18 | UCB Biopharma SRL | Process for the production of recombinant proteins |
| WO2024089277A2 (en) | 2022-10-27 | 2024-05-02 | Oxford University Innovation Limited | Antibodies |
| GB202304512D0 (en) | 2023-03-28 | 2023-05-10 | Univ Oxford Innovation Ltd | Antibodies |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| ES2225961T3 (es) | 1996-04-04 | 2005-03-16 | Unilever N.V. | Proteina de union a antigeno multivalente y multiespecifica. |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US6387981B1 (en) | 1999-10-28 | 2002-05-14 | 3M Innovative Properties Company | Radiopaque dental materials with nano-sized particles |
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| WO2002002781A1 (en) * | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| AU2001283496A1 (en) | 2000-07-25 | 2002-02-05 | Immunomedics, Inc. | Multivalent target binding protein |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MX2008010561A (es) | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Anticuerpos funcionales. |
| JP5374359B2 (ja) | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
| CA2654317A1 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| AU2008287195A1 (en) | 2007-07-06 | 2009-02-19 | Emergent Product Development Seattle, Llc | Binding peptides having a C-terminally disposed specific binding domain |
| WO2009018386A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| JP5485152B2 (ja) | 2007-08-15 | 2014-05-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 単一特異性および多特異性抗体ならびに使用方法 |
| WO2009032782A2 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| JP2011504740A (ja) | 2007-11-27 | 2011-02-17 | アブリンクス エン．ヴェー． | ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド |
| EA201100527A1 (ru) | 2008-09-26 | 2011-10-31 | Юсб Фарма С.А. | Биологические продукты |
| CN102164960A (zh) * | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| RU2598248C2 (ru) | 2009-04-02 | 2016-09-20 | Роше Гликарт Аг | Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab |
| KR20110124369A (ko) | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | 이중특이적 항ｅｒｂｂ3／항ｃｍｅｔ 항체 |
| CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| AU2011249782B2 (en) | 2010-05-06 | 2014-10-02 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies |
| MX340558B (es) | 2010-08-24 | 2016-07-14 | F Hoffmann-La Roche Ag * | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| UY34347A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| EP2578230A1 (en) | 2011-10-04 | 2013-04-10 | Trion Pharma Gmbh | Removal of Tumor Cells from Intraoperative Autologous Blood Salvage |
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| EP2776466B1 (en) * | 2011-11-11 | 2017-08-23 | UCB Biopharma SPRL | Albumin binding antibodies and binding fragments thereof |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2014
- 2014-06-25 GB GBGB1411320.3A patent/GB201411320D0/en not_active Ceased
-
2015
- 2015-06-25 BR BR112016027585-3A patent/BR112016027585A2/pt not_active Application Discontinuation
- 2015-06-25 US US15/321,055 patent/US11345760B2/en active Active
- 2015-06-25 MY MYPI2016704688A patent/MY176332A/en unknown
- 2015-06-25 CN CN201580033958.3A patent/CN106459216B/zh active Active
- 2015-06-25 RS RSP20191284 patent/RS59416B1/sr unknown
- 2015-06-25 EP EP19169534.5A patent/EP3556777B1/en active Active
- 2015-06-25 AU AU2015279128A patent/AU2015279128B2/en active Active
- 2015-06-25 HU HUE15732228A patent/HUE046027T2/hu unknown
- 2015-06-25 LT LTEP15732228.0T patent/LT3161007T/lt unknown
- 2015-06-25 ES ES19169534T patent/ES2866398T3/es active Active
- 2015-06-25 PL PL15732228T patent/PL3161007T3/pl unknown
- 2015-06-25 PT PT157322280T patent/PT3161007T/pt unknown
- 2015-06-25 EP EP15732228.0A patent/EP3161007B1/en active Active
- 2015-06-25 PL PL19169534T patent/PL3556777T3/pl unknown
- 2015-06-25 ME MEP-2019-274A patent/ME03539B/me unknown
- 2015-06-25 ES ES15732228T patent/ES2750649T3/es active Active
- 2015-06-25 SI SI201530888T patent/SI3161007T1/sl unknown
- 2015-06-25 RU RU2017102193A patent/RU2725812C2/ru active
- 2015-06-25 KR KR1020167035654A patent/KR102271204B1/ko active IP Right Grant
- 2015-06-25 MY MYPI2020002370A patent/MY195318A/en unknown
- 2015-06-25 JP JP2016575023A patent/JP6765974B2/ja active Active
- 2015-06-25 SG SG10201911670QA patent/SG10201911670QA/en unknown
- 2015-06-25 RS RS20210181A patent/RS61493B1/sr unknown
- 2015-06-25 CA CA2951609A patent/CA2951609C/en active Active
- 2015-06-25 DK DK15732228.0T patent/DK3161007T3/da active
- 2015-06-25 DK DK19169534.5T patent/DK3556777T3/da active
- 2015-06-25 LT LTEP19169534.5T patent/LT3556777T/lt unknown
- 2015-06-25 SI SI201531504T patent/SI3556777T1/sl unknown
- 2015-06-25 HU HUE19169534A patent/HUE053457T2/hu unknown
- 2015-06-25 SG SG11201609678YA patent/SG11201609678YA/en unknown
- 2015-06-25 MX MX2016015952A patent/MX2016015952A/es active IP Right Grant
- 2015-06-25 PT PT191695345T patent/PT3556777T/pt unknown
- 2015-06-25 WO PCT/EP2015/064409 patent/WO2015197772A1/en active Application Filing
-
2016
- 2016-11-16 IL IL249003A patent/IL249003B/en active IP Right Grant
- 2016-12-23 CL CL2016003324A patent/CL2016003324A1/es unknown
-
2019
- 2019-07-15 AU AU2019205981A patent/AU2019205981B2/en active Active
- 2019-10-01 HR HRP20191775TT patent/HRP20191775T1/hr unknown
- 2019-10-15 CY CY20191101082T patent/CY1122175T1/el unknown
-
2021
- 2021-03-08 HR HRP20210389TT patent/HRP20210389T1/hr unknown
- 2021-03-12 CY CY20211100214T patent/CY1123932T1/el unknown
-
2022
- 2022-05-02 US US17/734,253 patent/US20220267476A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210389T1 (hr) | Višespecifične konstrukcije antitijela | |
| HRP20201503T1 (hr) | MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79 | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| RU2021103288A (ru) | МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22 | |
| JP2020500538A5 (hr) | ||
| BR112019003775A2 (pt) | anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos | |
| MY186351A (en) | Multispecific antibodies | |
| HRP20170882T1 (hr) | Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| JP2018521638A5 (hr) | ||
| RS54846B1 (sr) | Novo anti-dr5 antitelo | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| HRP20240774T1 (hr) | Anti-il-33 antitijela i njihove upotrebe | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2017533694A5 (hr) | ||
| JP2012116856A5 (hr) | ||
| HRP20191590T1 (hr) | Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen |